Computer-aided de novo ligand design and docking/molecular dynamics study of Vitamin D receptor agonists

Abstract1α,25(OH)2D3, which is directly mediated by the vitamin D receptor (VDR), exerts a wide variety of biological actions. However, the treatment with 1α,25(OH)2D3 is limited because of its side effects. Many analogs and several nonsteroidal mimics with potent biological activity have been reported so far, and our rationale for designing the VDR agonists was on the basis of computer-aided drug design method by de novo design of A-ring and C/D-ring position of 1α,25(OH)2D3. Pyrimidine-2,4-diamine was selected as A-ring, and naphthalene and benzene were chosen as C/D-ring. By linking different components, a virtue compound library was obtained. To evaluate the contribution to activity of each component, we performed a series of automated molecular docking operations. Results revealed that the 19-dimethyl derivatives (the C-19 position correspond to C-20 in 1α,25(OH)2D3) show the favorable docking affinity to VDR. Moreover, the docking results are quite robust when further validated by molecular dynamics simulations. In addition, by free energy analysis using molecular mechanics-Poisson-Boltzmann surface area (MM-PBSA) method, the driving force of the binding between VDR and the ligands is proved to be hydrophobic interactions. Thus, a possible strategy to design new series of VDR agonists is proposed. The strategy can be successfully applied to explain the high potential activities of the 19-dimethyl derivatives. It is anticipated that the findings reported here may provide useful information for designing effective VDR agonists as well as the therapeutic treatment of VDR-related diseases.

[1]  M. Haussler,et al.  Biological Activity of CD‐Ring Modified 1α,25‐Dihydroxyvitamin D Analogues: C‐Ring and Five‐Membered D‐Ring Analogues , 2000 .

[2]  K. Chou,et al.  Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. , 2009, Biochemical and biophysical research communications.

[3]  M. Makishima,et al.  Ligands with a 3,3-diphenylpentane skeleton for nuclear vitamin D and androgen receptors: Dual activities and metabolic activation. , 2006, Bioorganic & medicinal chemistry.

[4]  Ricardo L. Mancera,et al.  The effect of a tightly bound water molecule on scaffold diversity in the computer-aided de novo ligand design of CDK2 inhibitors , 2006, Journal of molecular modeling.

[5]  R. Bouillon,et al.  Structure-function relationships in the vitamin D endocrine system. , 1995, Endocrine reviews.

[6]  Renxiao Wang,et al.  Comparative evaluation of 11 scoring functions for molecular docking. , 2003, Journal of medicinal chemistry.

[7]  M. Makishima,et al.  Vitamin D receptor: ligand recognition and allosteric network. , 2006, Journal of medicinal chemistry.

[8]  C. M. Hansen,et al.  Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. , 2000, Current pharmaceutical design.

[9]  R. Bouillon,et al.  Two novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo. , 2000, Cancer research.

[10]  N. Ito,et al.  A new class of vitamin D analogues that induce structural rearrangement of the ligand-binding pocket of the receptor. , 2009, Journal of medicinal chemistry.

[11]  H. Li,et al.  Effect of 1,25,28‐trihydroxyvitamin D2 and 1,24,25‐trihydroxyvitamin D3 on intestinal calbindin‐D9K mRNA and protein: Is there a correlation with intestinal calcium transport? , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  Marcela Madrid,et al.  Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase. , 2005, Journal of the American Chemical Society.

[13]  Y. Hashimoto,et al.  Practical synthesis and evaluation of the biological activities of 1alpha,25-dihydroxyvitamin D3 antagonists, 1alpha,25-dihydroxyvitamin D3-26,23-lactams. Designed on the basis of the helix 12-folding inhibition hypothesis. , 2006, Journal of medicinal chemistry.

[14]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[15]  L. Binderup,et al.  Calcipotriol (MC 903): pharmacokinetics in rats and biological activities of metabolites. A comparative study with 1,25(OH)2D3. , 1991, Biochemical pharmacology.

[16]  Alex J. Brown,et al.  Mechanisms for the selective actions of vitamin D analogues. , 2000, Current pharmaceutical design.

[17]  Á. Pascual,et al.  Nuclear hormone receptors and gene expression. , 2001, Physiological reviews.

[18]  Hiroaki Tokiwa,et al.  Interactions between 1α,25(OH)2D3 and residues in the ligand-binding pocket of the vitamin D receptor: A correlated fragment molecular orbital study , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[20]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[21]  Kuo-Chen Chou,et al.  Energetic analysis of the two controversial drug binding sites of the M2 proton channel in influenza A virus. , 2009, Journal of theoretical biology.

[22]  Kuo-Chen Chou,et al.  An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus. , 2008, Biochemical and biophysical research communications.

[23]  Hans-Joachim Böhm,et al.  On the use of LUDI to search the Fine Chemicals Directory for ligands of proteins of known three-dimensional structure , 1994, J. Comput. Aided Mol. Des..

[24]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[25]  D. R. Holland,et al.  Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand. , 1997, Journal of medicinal chemistry.

[26]  S. Peleg,et al.  Vitamin D analogs as modulators of vitamin D receptor action. , 2003, Current topics in medicinal chemistry.

[27]  G. Grodsky,et al.  Vitamin D deficiency inhibits pancreatic secretion of insulin. , 1980, Science.

[28]  H. DeLuca,et al.  Design, Synthesis, and Biological Evaluation of a 1α,25-Dihydroxy-19-norvitamin D3 Analogue with a Frozen A-Ring Conformation , 2007 .

[29]  C. Carlberg,et al.  Molecular evaluation of vitamin D3 receptor agonists designed for topical treatment of skin diseases. , 2001, The Journal of investigative dermatology.

[30]  R. Bouillon,et al.  Biologic activity of dihydroxylated 19‐nor‐(pre)vitamin D3 , 1993 .

[31]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[32]  K. Chou,et al.  Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. , 2007, Biochemical and biophysical research communications.

[33]  Glenville Jones,et al.  Vitamin D analogs--drug design based on proteins involved in vitamin D signal transduction. , 2003, Current drug targets. Immune, endocrine and metabolic disorders.

[34]  C. Carlberg,et al.  Structure Activity Relationship of Carboxylic Ester Antagonists of the Vitamin D3 Receptor , 2000 .

[35]  D. Case,et al.  Exploring protein native states and large‐scale conformational changes with a modified generalized born model , 2004, Proteins.

[36]  David S. Goodsell,et al.  A semiempirical free energy force field with charge‐based desolvation , 2007, J. Comput. Chem..

[37]  D. Rognan,et al.  Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. , 2000, Journal of medicinal chemistry.

[38]  P. Kollman,et al.  Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .

[39]  A. Norman,et al.  1α,25‐Dihydroxyvitamin D3‐26,23‐lactone analogs antagonize differentiation of human leukemia cells (HL‐60 cells) but not of human acute promyelocytic leukemia cells (NB4 cells) , 1999, FEBS letters.

[40]  B. Honig,et al.  Classical electrostatics in biology and chemistry. , 1995, Science.

[41]  C. Carlberg,et al.  Structure activity relationship of carboxylic ester antagonists of the vitamin D(3) receptor. , 2000, Molecular pharmacology.

[42]  H. Koeffler,et al.  Novel vitamin D(3) analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D(3), that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells. , 2001, Blood.

[43]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[44]  S. Yamada,et al.  Conformation-function relationship of vitamin D: conformational analysis predicts potential side-chain structure. , 1998, Journal of medicinal chemistry.

[45]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[46]  H. Nowicki,et al.  1,25-Dihydroxycholecalciferol: Identification of the Proposed Active Form of Vitamin D3 in the Intestine , 1971, Science.

[47]  R. Gibbs,et al.  Studies of vitamin D (calciferol) and its analogs. 35. Synthesis and biological activity of 9,11-dehydrovitamin D3 analogs: stereoselective preparation of 6.beta.-vitamin D vinylallenes and a concise enynol synthesis for preparing the A-ring , 1989 .

[48]  L. Sarandeses,et al.  Synthesis and conformational analysis of 17alpha,21-cyclo-22-unsaturated analogues of calcitriol. , 2007, The Journal of organic chemistry.